David Risinger
Stock Analyst at Leerink Partners
(4.52)
# 223
Out of 5,182 analysts
182
Total ratings
64.71%
Success rate
16.02%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Outperform | $66 → $85 | $66.20 | +28.40% | 2 | Apr 28, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Outperform | $46 | $20.92 | +119.94% | 1 | Apr 24, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Market Perform | $36 → $40 | $39.50 | +1.27% | 3 | Apr 1, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Outperform | $58 → $86 | $63.81 | +34.78% | 3 | Mar 16, 2026 | |
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $325.30 | +9.13% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $58.85 | +1.95% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $424.52 | +23.67% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $28.05 | +14.08% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $40.92 | +9.97% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $961.27 | +14.85% | 17 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $6.06 | +395.05% | 1 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $70 | $63.63 | +10.01% | 4 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $169 → $153 | $228.03 | -32.90% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $762 → $834 | $704.83 | +18.33% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $207.75 | -0.84% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $28.60 | +141.30% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $12.79 | +25.10% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $56.66 | +170.03% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $16.73 | -40.23% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $130.84 | -30.45% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $26.43 | +81.61% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $13.28 | +178.72% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $203.04 | -13.32% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $14.93 | +7.17% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $11.87 | +279.11% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.63 | +521.67% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $22.49 | +82.30% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $114.43 | +52.06% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $49.40 | +3.24% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $35.00 | -77.14% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $112.61 | -20.97% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.78 | -76.53% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $33.70 | -52.52% | 9 | Apr 2, 2020 |
AnaptysBio
Apr 28, 2026
Maintains: Outperform
Price Target: $66 → $85
Current: $66.20
Upside: +28.40%
First Tracks Biotherapeutics
Apr 24, 2026
Initiates: Outperform
Price Target: $46
Current: $20.92
Upside: +119.94%
Centessa Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: $36 → $40
Current: $39.50
Upside: +1.27%
Oruka Therapeutics
Mar 16, 2026
Maintains: Outperform
Price Target: $58 → $86
Current: $63.81
Upside: +34.78%
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $325.30
Upside: +9.13%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $58.85
Upside: +1.95%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $424.52
Upside: +23.67%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $28.05
Upside: +14.08%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $40.92
Upside: +9.97%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $961.27
Upside: +14.85%
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.06
Upside: +395.05%
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $63.63
Upside: +10.01%
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $228.03
Upside: -32.90%
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $704.83
Upside: +18.33%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $207.75
Upside: -0.84%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $28.60
Upside: +141.30%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $12.79
Upside: +25.10%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $56.66
Upside: +170.03%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $16.73
Upside: -40.23%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $130.84
Upside: -30.45%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $26.43
Upside: +81.61%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $13.28
Upside: +178.72%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $203.04
Upside: -13.32%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $14.93
Upside: +7.17%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $11.87
Upside: +279.11%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.63
Upside: +521.67%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $22.49
Upside: +82.30%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $114.43
Upside: +52.06%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $49.40
Upside: +3.24%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $35.00
Upside: -77.14%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $112.61
Upside: -20.97%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.78
Upside: -76.53%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $33.70
Upside: -52.52%